– The CONNEX programme (three identical phase 3 trials) found no significant improvement in cognition with 10 mg iclepertin versus placebo at 26 weeks (MCCB overall composite T-score adjusted mean difference 0.127; 95% CI -0.396 to 0.650; p=0.63).
– Iclepertin was well tolerated with on-treatment adverse event rates similar to placebo (66% vs 69%); no safety signal emerged.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.